Fingolimod 0.5 mg capsules- Test drug
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence
Conditions
Bioequivalence, Safety
Trial Timeline
Oct 29, 2015 → Jan 15, 2016
NCT ID
NCT05145621About Fingolimod 0.5 mg capsules- Test drug
Fingolimod 0.5 mg capsules- Test drug is a phase 1 stage product being developed by Alembic Pharmaceuticals for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT05145621. Target conditions include Bioequivalence, Safety.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05145621 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence